Oxidative markers and efficacy in Amyotrophic Lateral Sclerosis (ALS) phenotypes treated with Edaravone (Central Monitoring),
Role: PI,
Mitsubishi Tanabe Pharma America (MTPA),
(07/2024 - 07/2025)
Status: Approved
Oxidative markers and efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes treated with Edaravone,
Role: PI,
Mitsubishi Tanabe Pharma America (MTPA),
(02/2024 - 02/2025)
Status: Approved
LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT,
Role: Investigator,
Genentech, Inc.,
(01/2024)
Status: Approved
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS). Protocol: MT-1186-A02,
Role: PI,
Mitsubishi Tanabe Pharma America (MTPA),
(02/2023 - 02/2024)
Status: Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter study to evaluate the safety and efficacy of Ravulizumab in Complement-Inhibitor-Naïve adult patients with Generalized Myasthenia Gravis: Protocol # ALXN1210-MG-306,
Role: PI,
Alexion Pharmaceuticals,
(08/2022 - 08/2023)
Status: Completed
Internal
Evaluation of clinical grading scores in motor neuron disease,
Role: PI,
LLU Dept. of Neurology,
(08/2024 - 08/2025)
Status: Approved
Understanding the spectrum of amyotrophic lateral sclerosis,
Role: PI,
LLU Dept. of Neurology,
(02/2024 - 02/2025)
Status: Approved
Evaluating multidisciplinary care in the neurology setting,
Role: PI,
LLU Dept. of Neurology,
(04/2023 - 03/2024)
Status: Completed
Study to Identify Autoantibodies Associated with Amyotrophic Lateral Sclerosis (ALS),
Role: PI,
LLU Dept. of Neurology,
(02/2022)
Status: Approved
Exploring functional benefits of the mobile arm support for individuals with Amyotrophic lateral sclerosis (ALS),
Role: Investigator,
LLU Dept. of Occupational Therapy,
(03/2018 - 03/2019)
Status: Completed
Non-Profit Organization
MDA Multidisciplinary Clinic at Loma Linda University Health,
Role: PD/PI,
Muscular Dystrophy Association,
(01/2017 - 06/2027)
Status: Awarded
Neuromuscular ALS/NMD Program,
Role: Principal Investigator,
The Community Foundation,
(11/2016 - 11/2018)
Status: Closed